Promotion: Investments in small cap shares involves a high degree of risk and are not suitable for all investors. Companies listed on the AIM or Aquis market can be highly volatile and are considered high-risk speculative investments.
%20(500%20x%20600%20px).png)
MedPal AI transforms fragmented data from wearables and clinical sources into personalised, actionable health insights. At the intersection of wellness, private healthcare, and telemedicine, it aims to make proactive support both intelligent and accessible. With the AI healthcare market projected to grow at a CAGR of 38.6%² and the wearable medical devices market expected to hit $325 billion by 2032,³ the need for integrated, meaningful data interpretation is growing rapidly.
MedPal’s platform-agnostic AI connects siloed apps and devices, delivering real-time nudges, early alerts, and care pathways. With scalable revenue from direct users, enterprise clients, and a 1M-user pilot with ePassi, MedPal is building a next-gen digital health companion to lead the future of connected wellness.
MedPal AI transforms fragmented data from wearables and clinical sources into personalised, actionable health insights. At the intersection of wellness, private healthcare, and telemedicine, it aims to make proactive support both intelligent and accessible. With the AI healthcare market projected to grow at a CAGR of 38.6%² and the wearable medical devices market expected to hit $325 billion by 2032,³ the need for integrated, meaningful data interpretation is growing rapidly.
MedPal’s platform-agnostic AI connects siloed apps and devices, delivering real-time nudges, early alerts, and care pathways. With scalable revenue from direct users, enterprise clients, and a 1M-user pilot with ePassi, MedPal is building a next-gen digital health companion to lead the future of connected wellness.
.png)
Teladoc Health evolved from a telemedicine provider into a full-service virtual care platform, integrating AI, remote monitoring, and chronic care into a seamless user experience. Its model shows what’s possible when digital health tools scale effectively.
Like Teladoc, MedPal combines AI-driven insights with a dual go-to-market strategy of "direct-to-consumer" and "enterprise". By unifying data from wearables, health apps, and lifestyle inputs, MedPal’s platform delivers real-time nudges, personalised health tips, and clinical handoffs through its Health Guardian feature.
Proven Revenue Engine: In 2024, Teladoc generated USD 2.6 billion in revenue, largely from subscriptions and enterprise contracts.⁴ Its hybrid model, where users and businesses pay for access to value-adding care, mirrors MedPal’s DTC + B2B strategy.
High-Multiple Valuation: As of July 2025, Teladoc had a market cap of USD 24.3 billion, despite broader market headwinds. This reflects investor confidence in platform-driven care solutions that improve outcomes and reduce system-wide costs.⁵
Platform Synergy: Teladoc serves 80+ million people worldwide, including partnerships with employers, insurers, and government systems.⁶ MedPal could tap into similar synergies by acting as a data bridge between individual users, health insurers, and digital care providers, making personal health data more useful and profitable for everyone.
Teladoc’s rise shows the value of integrating AI and telehealth into a single, data-rich ecosystem. By offering proactive, personalised support to consumers and value to insurers and care providers, MedPal can carve out its own category and potentially exceed Teladoc’s pace of scale by starting at the data layer.
DOWNLOAD FREE REPORT
.png)
Fill out the short form below to get instant access to this free report revealing our Top 10 UK small-cap stock picks for July,
.png)
MedPal sits at the intersection of several high-growth trends: AI in healthcare, wearables, and telehealth. Below, we highlight three standout companies that have scaled successfully by unifying user data, delivering personalised care, and monetising through hybrid consumer– enterprise models.
Noom combines behavioural science with AI-driven coaching to help users form better health habits. With over 45 million global users, its personalised app delivers real-time nudges, wellness tracking, and psychology-based interventions.⁷ Its premium subscription model and evidence-based results helped it raise over $650 million in funding and target a valuation exceeding $3.7 billion.⁸ Like MedPal, Noom thrives by turning data and daily engagement into long-term behavioural change.
Fitbit helped pioneer the consumer wearable health market, selling over 120 million devices.⁹ By creating a platform that gamifies personal health and integrates with broader care ecosystems, Fitbit became a trusted name in preventative wellness. MedPal builds on this model but goes further, applying AI to unify data across any wearable or health app.
This digital health platform connects users to medical professionals, prescription treatments, and wellness products through a mobile-first experience.¹⁰ It scaled rapidly through DTC marketing, and now offers B2B solutions too. Valued at over $2 billion, Hims & Hers shows how personalisation + trust + simplicity can create sticky, scalable health brands, a key part of MedPal’s vision.
MedPal sits at the intersection of several high-growth trends: AI in healthcare, wearables, and telehealth. Below, we highlight three standout companies that have scaled successfully by unifying user data, delivering personalised care, and monetising through hybrid consumer– enterprise models.
Noom combines behavioural science with AI-driven coaching to help users form better health habits. With over 45 million global users, its personalised app delivers real-time nudges, wellness tracking, and psychology-based interventions.⁷ Its premium subscription model and evidence-based results helped it raise over $650 million in funding and target a valuation exceeding $3.7 billion.⁸ Like MedPal, Noom thrives by turning data and daily engagement into long-term behavioural change.
Fitbit helped pioneer the consumer wearable health market, selling over 120 million devices.⁹ By creating a platform that gamifies personal health and integrates with broader care ecosystems, Fitbit became a trusted name in preventative wellness. MedPal builds on this model but goes further, applying AI to unify data across any wearable or health app.
This digital health platform connects users to medical professionals, prescription treatments, and wellness products through a mobile-first experience.¹⁰ It scaled rapidly through DTC marketing, and now offers B2B solutions too. Valued at over $2 billion, Hims & Hers shows how personalisation + trust + simplicity can create sticky, scalable health brands, a key part of MedPal’s vision.
30+ years of experience in financial markets analysing Bonds, Equities, Derivatives, Macro Strategy and Technical Analysis
MedPal AI is coming to market at the optimum moment. Their offering looks to marry up wearable health devices and their users with actionable AI driven prompts and advice derived from the real data the app receives and holds. If you think of the whole chain, from device to user to prompts leading into premium benefits like referrals to medical professionals, leading to better data at the treatment end for drug creation and health outcomes, then you can see value and cost savings everywhere. The back end is developing quickly at the clinician point but there is much fragmentation at the user end.
MedPal is device agnostic and can bring all your data and app usage into a centralised hub. The user potential is huge with insurance providers keen on reducing costs which ultimately benefit through lower premiums. Already partnered with ePassi giving access to at least 1m clients who already have health benefits like insurance and gym memberships and should be willing triallists. These are the kind of high value subset that tend to pay for premium services.
The wider exposure direct to consumer has the potential for an early boost with the ePassi downloads putting them high up the dowloaded app list for exposure. Regulation is supportive and the US is currently discussing with stakeholders about encouraging interoperability of device and data, whilst also encouraging mass take up of wearable health devices.
So MedPal is at the right time, set for early mover traffic and will be providing quick real-time engagement with users which is the key for retention and upgrade to premium services. The stock should have the ability to react positively to high margin partnership, contract wins and user downloads releases.
30+ years of experience in financial markets analysing Bonds, Equities, Derivatives, Macro Strategy and Technical Analysis
MedPal AI is coming to market at the optimum moment. Their offering looks to marry up wearable health devices and their users with actionable AI driven prompts and advice derived from the real data the app receives and holds. If you think of the whole chain, from device to user to prompts leading into premium benefits like referrals to medical professionals, leading to better data at the treatment end for drug creation and health outcomes, then you can see value and cost savings everywhere. The back end is developing quickly at the clinician point but there is much fragmentation at the user end.
MedPal is device agnostic and can bring all your data and app usage into a centralised hub. The user potential is huge with insurance providers keen on reducing costs which ultimately benefit through lower premiums. Already partnered with ePassi giving access to at least 1m clients who already have health benefits like insurance and gym memberships and should be willing triallists. These are the kind of high value subset that tend to pay for premium services.
The wider exposure direct to consumer has the potential for an early boost with the ePassi downloads putting them high up the dowloaded app list for exposure.
Regulation is supportive and the US is currently discussing with stakeholders about encouraging interoperability of device and data, whilst also encouraging mass take up of wearable health devices.
So MedPal is at the right time, set for early mover traffic and will be providing quick real-time engagement with users which is the key for retention and upgrade to premium services.
The stock should have the ability to react positively to high margin partnership, contract wins and user downloads releases.
1:
5: https://finance.yahoo.com/quote/TDOC
6: https://www.teladochealth.com/why-teladoc-health/
7: https://www.fastcompany.com/most-innovative-companies/2021/noom
8: https://techcrunch.com/2021/05/25/noom-raises-540m-for-its-health-coaching-platform/
9: https://www.businessofapps.com/data/fitbit-statistics/
10: https://investors.forhims.com/
Nothing in the above article should be considered investment advice.
Small Cap or Aquis listed companies can be highly illiquid making them difficult to sell at the quoted price, and in some cases, it may be difficult to sell them at any price. Small Cap or Aquis listed companies can have a large bid / offer spread which means there could be a large difference between the buying and selling price. Companies listed on the Aquis market can be highly volatile and are considered high risk speculative investments. The value of your investment can go down as well as up, your Capital is at risk you may not get back the amount invested. Investments in IPO’s & RTO’s involve a high degree of risk and are not suitable for all investors. All investments made into an IPO, RTO in a secondary issue should always be made solely based on the information provided in the relevant prospectus and any other supplementary documentation. Please ensure that you fully understand the risks involved. If in any doubt, please seek independent financial advice. This document is published by Clear Capital Markets and does not constitute a solicitation or personal recommendation for the purchase or sale of investment. The investments referred to may not be suitable for all investors. Any data or views given should not be construed as investment advice. Every effort is made to ensure the accuracy of the information, but no assurance or warranties are given. Clear Capital Markets Limited is authorised and regulated by the Financial Conduct Authority FRN 706689.
Clear Capital Markets Corporate Broking acts as a Corporate Broker to MedPal and holds warrants and shares in the company. Employees and/or directors of Clear Capital Markets may deal in shares of MedPal for their own personal accounts. These scenarios may give rise to a conflict of interest where Clear Capital Markets also provides clients with an advisory service for transactions involving MedPal. The firm has established Conflicts of Interest (“COI”) and Personal Account Dealing (“PAD”) policies to mitigate the risk of a conflict causing damage to the interests of its clients. The measures taken include (i) enforcing minimum holding or ‘lock-in’ periods; and (ii) requiring internal review and approval from the compliance department for employees or directors entering into personal transactions involving MedPal. The COI and PAD policies are available upon request. Before Clear Capital Markets proceeds with a placing, a number of factors are considered including: liquidity of stock, company diversification, market capitalisation and potential news flow. Only once minimum criteria are satisfied would we elect to proceed. Any remuneration payable to Clear Capital Markets has no bearing on whether it proceeds with a placing. These administrative controls mitigate the risk of a conflict causing damage to the interest of a client, but the inherent risks of this business model cannot be eliminated. Accordingly, Clear Capital Markets is required to disclose this conflict to help clients to assess the service that they are being offered in light of Clear Capital’s own interests, and to decide on the extent (if at all) to which they will rely on, or proceed with, the service.
We will reach out for a quick introductory fact find to see how we can best serve your specific needs and arrange a convenient time for a consultation with a member of the appropriate specialist team.
An Advisory Broker will contact you for a deeper fact find and share information on how we can best enhance your portfolio.
We will conduct a full RCP in accordance with FCA regulations to ensure that your appropriate risk profile is set. You will then have access to an extensive suite of investments, supported by your dedicated Advisory Broker.
